Cargando…

315. Standardized Measurement of SARS-CoV-2 Viral Load Over Time in Respiratory Compartments and in Response to Remdesivir Treatment

BACKGROUND: Two years into the pandemic, clinicians do not have access to a standardized measurement of SARS-CoV-2 viral load (VL) that allows for VL comparison across clinical specimens and different assays. Reliable VL measurement in diverse respiratory specimens, over time, and in response to tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Beckwith, Curt, Sam, Soya, Novitsky, Vladimir, Shin, Jimin, Lethbridge, Kevin, Steingrimsson, Jon, Sahu, Sujata, Rapoza, Kim, Chandran, Karen, Mariano, Vincent J, Bazerman, Lauri, Hipolito, Evelyn R, Diaz, Isabella, Carnevale, Daniella M, Gillani, Fizza S, Caliendo, Angela, Kantor, Rami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751954/
http://dx.doi.org/10.1093/ofid/ofac492.393
_version_ 1784850599753285632
author Beckwith, Curt
Sam, Soya
Novitsky, Vladimir
Shin, Jimin
Lethbridge, Kevin
Steingrimsson, Jon
Sahu, Sujata
Rapoza, Kim
Chandran, Karen
Mariano, Vincent J
Bazerman, Lauri
Hipolito, Evelyn R
Diaz, Isabella
Carnevale, Daniella M
Gillani, Fizza S
Caliendo, Angela
Kantor, Rami
author_facet Beckwith, Curt
Sam, Soya
Novitsky, Vladimir
Shin, Jimin
Lethbridge, Kevin
Steingrimsson, Jon
Sahu, Sujata
Rapoza, Kim
Chandran, Karen
Mariano, Vincent J
Bazerman, Lauri
Hipolito, Evelyn R
Diaz, Isabella
Carnevale, Daniella M
Gillani, Fizza S
Caliendo, Angela
Kantor, Rami
author_sort Beckwith, Curt
collection PubMed
description BACKGROUND: Two years into the pandemic, clinicians do not have access to a standardized measurement of SARS-CoV-2 viral load (VL) that allows for VL comparison across clinical specimens and different assays. Reliable VL measurement in diverse respiratory specimens, over time, and in response to treatments such as remdesivir (RDV), could better inform treatment and prevention. METHODS: To investigate the use of a standardized VL assay in respiratory specimens, we enrolled patients hospitalized with COVID-19 in Providence, RI, with/without RDV exposure; collected serial samples from 4 compartments (nasopharyngeal-NP, nasal-NA, oropharyngeal-OP, saliva-SA) in 3 visits during the 1st week of hospitalization; and characterized SARS-CoV-2 VL using a ChromaCode HDPCR™ quantitative research use only assay, calibrated to the first World Health Organization (WHO) International Standard (IS). Linear mixed effects models and associated regression coefficients were used to analyze inter-compartmental VL differences at enrollment, over time, and with/without RDV. RESULTS: Of 35 participants (60% male; 70% White, 14% Hispanic/Latino, 49% RDV exposure), all had visit 1 samples (median hospital day 1, IQR 0-2; pre-RDV for those exposed); 80% visit 2 samples (median hospital day 2, IQR 1-8); and 37% visit 3 samples (median hospital day 4, IQR 3-7). Overall, 38 NP, 67 NA, 57 OP, and 67 SA samples were collected. Mean log VLs (Log(10)IU/mL) differed by compartment at visit 1 (NP 6.3, NA 4.9, OP 4.1, SA 5.6, p=0.0001) and significantly decreased over time in all compartments (p< 0.04 for all comparisons). Log VL change over time was not significantly different between compartments or between people treated/not treated with RDV. CONCLUSION: We successfully measured respiratory intercompartmental SARS-CoV-2 VL differences among hospitalized patients using a standardized assay calibrated to the WHO IS. Dissemination of standardized VL measurement methods will allow accurate VL comparisons across assay types quantified in IU/mL and improve assessment of the impact of COVID-19 treatments. Inter-compartmental VL differences at baseline may indicate sampling variability or different viral burden. RDV did not appear to accelerate viral decay. DISCLOSURES: Curt Beckwith, MD, Gilead Sciences, Inc: Grant/Research Support Jon Steingrimsson, PhD, Gilead: Grant/Research Support Angela Caliendo, MD, PhD, ChromaCode: Advisor/Consultant|Danaher/Cepheid: Advisor/Consultant|First Light: Advisor/Consultant|Hologic: Grant/Research Support|ID Connect: Advisor/Consultant|Quidel: Advisor/Consultant|Visby: Advisor/Consultant Rami Kantor, MD, Gilead Sciences: Grant/Research Support.
format Online
Article
Text
id pubmed-9751954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97519542022-12-16 315. Standardized Measurement of SARS-CoV-2 Viral Load Over Time in Respiratory Compartments and in Response to Remdesivir Treatment Beckwith, Curt Sam, Soya Novitsky, Vladimir Shin, Jimin Lethbridge, Kevin Steingrimsson, Jon Sahu, Sujata Rapoza, Kim Chandran, Karen Mariano, Vincent J Bazerman, Lauri Hipolito, Evelyn R Diaz, Isabella Carnevale, Daniella M Gillani, Fizza S Caliendo, Angela Kantor, Rami Open Forum Infect Dis Abstracts BACKGROUND: Two years into the pandemic, clinicians do not have access to a standardized measurement of SARS-CoV-2 viral load (VL) that allows for VL comparison across clinical specimens and different assays. Reliable VL measurement in diverse respiratory specimens, over time, and in response to treatments such as remdesivir (RDV), could better inform treatment and prevention. METHODS: To investigate the use of a standardized VL assay in respiratory specimens, we enrolled patients hospitalized with COVID-19 in Providence, RI, with/without RDV exposure; collected serial samples from 4 compartments (nasopharyngeal-NP, nasal-NA, oropharyngeal-OP, saliva-SA) in 3 visits during the 1st week of hospitalization; and characterized SARS-CoV-2 VL using a ChromaCode HDPCR™ quantitative research use only assay, calibrated to the first World Health Organization (WHO) International Standard (IS). Linear mixed effects models and associated regression coefficients were used to analyze inter-compartmental VL differences at enrollment, over time, and with/without RDV. RESULTS: Of 35 participants (60% male; 70% White, 14% Hispanic/Latino, 49% RDV exposure), all had visit 1 samples (median hospital day 1, IQR 0-2; pre-RDV for those exposed); 80% visit 2 samples (median hospital day 2, IQR 1-8); and 37% visit 3 samples (median hospital day 4, IQR 3-7). Overall, 38 NP, 67 NA, 57 OP, and 67 SA samples were collected. Mean log VLs (Log(10)IU/mL) differed by compartment at visit 1 (NP 6.3, NA 4.9, OP 4.1, SA 5.6, p=0.0001) and significantly decreased over time in all compartments (p< 0.04 for all comparisons). Log VL change over time was not significantly different between compartments or between people treated/not treated with RDV. CONCLUSION: We successfully measured respiratory intercompartmental SARS-CoV-2 VL differences among hospitalized patients using a standardized assay calibrated to the WHO IS. Dissemination of standardized VL measurement methods will allow accurate VL comparisons across assay types quantified in IU/mL and improve assessment of the impact of COVID-19 treatments. Inter-compartmental VL differences at baseline may indicate sampling variability or different viral burden. RDV did not appear to accelerate viral decay. DISCLOSURES: Curt Beckwith, MD, Gilead Sciences, Inc: Grant/Research Support Jon Steingrimsson, PhD, Gilead: Grant/Research Support Angela Caliendo, MD, PhD, ChromaCode: Advisor/Consultant|Danaher/Cepheid: Advisor/Consultant|First Light: Advisor/Consultant|Hologic: Grant/Research Support|ID Connect: Advisor/Consultant|Quidel: Advisor/Consultant|Visby: Advisor/Consultant Rami Kantor, MD, Gilead Sciences: Grant/Research Support. Oxford University Press 2022-12-15 /pmc/articles/PMC9751954/ http://dx.doi.org/10.1093/ofid/ofac492.393 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Beckwith, Curt
Sam, Soya
Novitsky, Vladimir
Shin, Jimin
Lethbridge, Kevin
Steingrimsson, Jon
Sahu, Sujata
Rapoza, Kim
Chandran, Karen
Mariano, Vincent J
Bazerman, Lauri
Hipolito, Evelyn R
Diaz, Isabella
Carnevale, Daniella M
Gillani, Fizza S
Caliendo, Angela
Kantor, Rami
315. Standardized Measurement of SARS-CoV-2 Viral Load Over Time in Respiratory Compartments and in Response to Remdesivir Treatment
title 315. Standardized Measurement of SARS-CoV-2 Viral Load Over Time in Respiratory Compartments and in Response to Remdesivir Treatment
title_full 315. Standardized Measurement of SARS-CoV-2 Viral Load Over Time in Respiratory Compartments and in Response to Remdesivir Treatment
title_fullStr 315. Standardized Measurement of SARS-CoV-2 Viral Load Over Time in Respiratory Compartments and in Response to Remdesivir Treatment
title_full_unstemmed 315. Standardized Measurement of SARS-CoV-2 Viral Load Over Time in Respiratory Compartments and in Response to Remdesivir Treatment
title_short 315. Standardized Measurement of SARS-CoV-2 Viral Load Over Time in Respiratory Compartments and in Response to Remdesivir Treatment
title_sort 315. standardized measurement of sars-cov-2 viral load over time in respiratory compartments and in response to remdesivir treatment
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751954/
http://dx.doi.org/10.1093/ofid/ofac492.393
work_keys_str_mv AT beckwithcurt 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT samsoya 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT novitskyvladimir 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT shinjimin 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT lethbridgekevin 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT steingrimssonjon 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT sahusujata 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT rapozakim 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT chandrankaren 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT marianovincentj 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT bazermanlauri 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT hipolitoevelynr 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT diazisabella 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT carnevaledaniellam 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT gillanifizzas 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT caliendoangela 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment
AT kantorrami 315standardizedmeasurementofsarscov2viralloadovertimeinrespiratorycompartmentsandinresponsetoremdesivirtreatment